Behavioral, Clinical, and Pathological Characterization of Acid Metalliferous Water Toxicity in Mallards

J. Isanhart,Hongmei Wu,K. Pandher,R. K. MacRae,S. Cox,M. Hooper

DOI: https://doi.org/10.1007/s00244-011-9657-z

2011-03-19

Archives of Environmental Contamination and Toxicology

Abstract:

What problem does this paper attempt to address?

Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

Christian Vaccarin,Guido Veit,Tamas Hegedus,Odalys Torres,Adriana Chilin,Gergely L Lukacs,Giovanni Marzaro

DOI: https://doi.org/10.1021/acs.jmedchem.4c00685

2024-08-22

Abstract:Cystic fibrosis (CF) is caused by the functional expression defect of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Despite the recent success in CFTR modulator development, the available correctors only partially restore the F508del-CFTR channel function, and several rare CF mutations show resistance to available drugs. We previously identified compound 4172 that synergistically rescued the F508del-CFTR folding defect in combination with the existing corrector drugs VX-809 and VX-661. Here, novel CFTR correctors were designed by applying a classical medicinal chemistry approach on the 4172 scaffold. Molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were conducted to propose a plausible binding site and design more potent and effective analogs. We identified three optimized compounds, which, in combination with VX-809 and the investigational corrector 3151, increased the plasma membrane density and function of F508del-CFTR and other rare CFTR mutants resistant to the currently approved therapies.
Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector

Mathieu Pizzonero,Rhalid Akkari,Xavier Bock,Romain Gosmini,Elsa De Lemos,Béranger Duthion,Gregory Newsome,Thi-Thu-Trang Mai,Virginie Roques,Hélène Jary,Jean-Michel Lefrancois,Laetitia Cherel,Vanessa Quenehen,Marielle Babel,Nuria Merayo,Natacha Bienvenu,Oscar Mammoliti,Ghjuvanni Coti,Adeline Palisse,Marlon Cowart,Anurupa Shrestha,Stephen Greszler,Steven Van Der Plas,Koen Jansen,Pieter Claes,Mia Jans,Maarten Gees,Monica Borgonovi,Gert De Wilde,Katja Conrath

DOI: https://doi.org/10.1021/acs.jmedchem.3c01790

IF: 8.039

2024-03-26

Journal of Medicinal Chemistry

Abstract:Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein. This epithelial anion channel regulates the active transport of chloride and bicarbonate ions across membranes. Mutations result in reduced surface expression of CFTR channels with impaired functionality. Correctors are small molecules that support the trafficking of CFTR to increase its membrane expression. Such correctors can have different mechanisms of action. Combinations may result in...

chemistry, medicinal
Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

Yihong Fan,Corina Balut,Sara Alani,Ying Jia,Bo Liu,Xueqing Wang,Wenqing Gao,Tzyh-Chang Hwang,Douglas Cyr,Katja Conrath,Chris Tse,Ashvani K. Singh,Arlene M. Manelli,Andrew M. Swensen,Torben R. Neelands,Timothy A. Vortherms,Xenia B. Searle,Hong Y. Ren,Philip R. Kym

DOI: https://doi.org/10.1124/jpet.119.261800

2019-11-15

Journal of Pharmacology and Experimental Therapeutics

Abstract:Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease in Caucasians caused by pathogenic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (CFTR). Significant small molecule therapeutic advances over the past two decades have been made to target the defective CFTR protein and enhance its function. To address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in CF, two biomolecular activities are required, namely, correctors to increase the amount of properly folded F508delCFTR levels at the cell surface and potentiators to allow the effective opening, i.e., function of the F508delCFTR channel. Combined, these activities enhance chloride ion transport yielding improved hydration of the lung surface and subsequent restoration of mucociliary clearance. To enhance clinical benefits to CF patients, a complementary triple combination therapy consisting of two corrector molecules, type 1 (C1) and type 2, with additive mechanisms along with a potentiator are being investigated in the clinic for maximum restoration of mutated CFTR function. We report the identification and in vitro biologic characterization of ABBV-2222/GLPG2222 (4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid),—a novel, potent, and orally bioavailable C1 corrector developed by AbbVie-Galapagos and currently in clinical trials—which exhibits substantial improvements over the existing C1 correctors. This includes improvements in potency and drug-drug interaction (DDI) compared with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (VX-809, Lumacaftor) and improvements in potency and efficacy compared with 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide (VX-661, Tezacaftor). ABBV-2222/GLPG2222 exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 value <10 nM.SIGNIFICANCE STATEMENTTo address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in cystic fibrosis, AbbVie-Galapagos has developed ABBV-2222/GLPG2222, a novel, potent, and orally bioavailable C1 corrector of this protein. ABBV-2222/GLPG2222, which is currently in clinical trials, exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR and substantial improvements over the existing C1 correctors.

pharmacology & pharmacy
[Mucoadhesive oral tablets--a modern dosage form with controlled drug release].

M. Dostálová,M. Rabišková

2000-03-01

Abstract:The review paper summarizes the principal pharmaceutical and medical information about the hitherto achieved results in the development of bioadhesive dosage form concentrating on mucoadhesive oral tablets. The site of administration of the tablets is the facial pocket. Due to specific properties of the mucous layer on the buccal mucosa and mucoadhesive polymers from which the tablets are manufactured, tablets adhere to the mucosa. The adhesion may take a certain period of time and during the whole period the active ingredient is gradually released. Absorption of the drug through the mucous membrane of the oral cavity has a number of advantages, in particular with respect to the stability of the drug. Various types of mucoadhesive tablets are being developed. The system releasing the drug only in one direction, i.e. direct to the mucosa, seems to be very advantageous. In the evaluation of mucoadhesive tablets, two parameters are of particular importance, the bioadhesive force and the rate of drug release. Oral mucoadhesive tablets can be employed in the treatment of both systemic and local diseases.
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors

Giada Righetti,Monica Casale,Nara Liessi,Bruno Tasso,Annalisa Salis,Michele Tonelli,Enrico Millo,Nicoletta Pedemonte,Paola Fossa,Elena Cichero

DOI: https://doi.org/10.3390/ijms21218084

IF: 5.6

2020-10-29

International Journal of Molecular Sciences

Abstract:Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. Different mutations involving the cystic fibrosis transmembrane regulator protein (CFTR) gene, which encodes the CFTR channel, are involved in CF. A number of life-prolonging therapies have been conceived and deeply investigated to combat this disease. Among them, the administration of the so-called CFTR modulators, such as correctors and potentiators, have led to quite beneficial effects. Recently, based on QSAR (quantitative structure activity relationship) studies, we reported the rational design and synthesis of compound 2, an aminoarylthiazole-VX-809 hybrid derivative exhibiting promising F508del-CFTR corrector ability. Herein, we explored the docking mode of the prototype VX-809 as well as of the aforementioned correctors in order to derive useful guidelines for the rational design of further analogues. In addition, we refined our previous QSAR analysis taking into account our first series of in-house hybrids. This allowed us to optimize the QSAR model based on the chemical structure and the potency profile of hybrids as F508del-CFTR correctors, identifying novel molecular descriptors explaining the SAR of the dataset. This study is expected to speed up the discovery process of novel potent CFTR modulators.
Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

Zhiwei Cai,Jia Liu,Hongyu Li,David N. Sheppard

DOI: https://doi.org/10.1038/aps.2011.71

IF: 7.169

2011-01-01

Acta Pharmacologica Sinica

Abstract:The mutation F508del is the commonest cause of the genetic disease cystic fibrosis (CF). CF disrupts the function of many organs in the body, most notably the lungs, by perturbing salt and water transport across epithelial surfaces. F508del causes harm in two principal ways. First, the mutation prevents delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) to its correct cellular location, the apical (lumen-facing) membrane of epithelial cells. Second, F508del perturbs the Cl(-) channel function of CFTR by disrupting channel gating. Here, we discuss the development of rational new therapies for CF that target F508del-CFTR. We highlight how structural studies provide new insight into the role of F508 in the regulation of channel gating by cycles of ATP binding and hydrolysis. We emphasize the use of high-throughput screening to identify lead compounds for therapy development. These compounds include CFTR correctors that restore the expression of F508del-CFTR at the apical membrane of epithelial cells and CFTR potentiators that rescue the F508del-CFTR gating defect. Initial results from clinical trials of CFTR correctors and potentiators augur well for the development of small molecule therapies that target the root cause of CF: mutations in CFTR.
Perceptual Comparisons with Pictures and Environmental Sounds

P. Goolkasian,Alexandra Stubblefield

Abstract:Perceptual Comparisons with Pictures and Environmental Sounds Paula Goolkasian UNC Charlotte Alexandra Stubblefield UNC Charlotte Abstract: This research involves perceptual comparisons with cues that vary in one of four ways (picture, sound, spoken word or printed word) and with targets that are either pictures or environmental sounds. Students were required to match cue-target pairs and determine whether the 2 successive events represented features drawn from the same item. Both the perceptual/linguistic format and the modality of the cue influenced responses to pictures and environmental sounds, but the cue type effects were qualified by same/different response type and with picture targets by left or right presentation location. These results provide some additional evidence of processing asymmetry when pictures are directed to either the right or left hemisphere, as well as for some asymmetries in cross modal cueing. Implications of these findings for theories of multisensory processing and models of object recognition are discussed.
Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.

Aaron D Mills,Choong Yoo,Jeffrey D Butler,Baoxue Yang,A S Verkman,Mark J Kurth

DOI: https://doi.org/10.1016/j.bmcl.2009.11.020

IF: 2.94

2009-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A developing therapy of cystic fibrosis caused by the DeltaF508 mutation in CFTR employs correction of defective CFTR chloride channel gating by a 'potentiator' and of defective CFTR protein folding by a 'corrector'. Based on SAR data for phenylglycine-type potentiators and bithiazole correctors, we designed a hybrid molecule incorporating an enzymatic hydrolysable linker to deliver the potentiator (PG01) fragment 2 and the corrector (Corr-4a) fragment 13. The hybrid molecule 14 contained PG01-OH and Corr-4a-linker-CO(2)H moieties, linked with an ethylene glycol spacer through an ester bond. The potentiator 2 and corrector 13 fragments (after cleavage) had low micromolar potency for restoration of DeltaF508-CFTR channel gating and cellular processing, respectively. Cleavage of hybrid molecule 14 by intestinal enzymes under physiological conditions produced the active potentiator 2 and corrector fragments 13, providing proof-of-concept for small-molecule potentiator-corrector hybrids as a single drug therapy for CF caused by the DeltaF508 mutation.
When lightning strikes.

J. Mervis

DOI: https://doi.org/10.1126/science.329.5989.270-c

IF: 56.9

2010-07-16

Science

Abstract:The idea that teachers are an essential component in learning about science might seem obvious to educators and scientists. But when science is absent from the curriculum, teachers don9t have much of a chance to shine. National Lab Day, created by neuroscientist-turned-Internet-entrepreneur Jack Hidary, is designed to inject more science into the classroom, using outside scientists as a vehicle.
Design and synthesis of a hybrid potentiator–corrector agonist of the cystic fibrosis mutant protein ΔF508-CFTR

Aaron D. Mills,Choong Yoo,Jeffrey D. Butler,Baoxue Yang,A.S. Verkman,Mark J. Kurth

DOI: https://doi.org/10.1016/j.bmcl.2009.11.020

IF: 2.94

2010-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:A developing therapy of cystic fibrosis caused by the ΔF508 mutation in CFTR employs correction of defective CFTR chloride channel gating by a ‘potentiator’ and of defective CFTR protein folding by a ‘corrector’. Based on SAR data for phenylglycine-type potentiators and bithiazole correctors, we designed a hybrid molecule incorporating an enzymatic hydrolysable linker to deliver the potentiator (PG01) fragment 2 and the corrector (Corr-4a) fragment 13. The hybrid molecule 14 contained PG01-OH and Corr-4a–linker–CO2H moieties, linked with an ethylene glycol spacer through an ester bond. The potentiator 2 and corrector 13 fragments (after cleavage) had low micromolar potency for restoration of ΔF508-CFTR channel gating and cellular processing, respectively. Cleavage of hybrid molecule 14 by intestinal enzymes under physiological conditions produced the active potentiator 2 and corrector fragments 13, providing proof-of-concept for small-molecule potentiator–corrector hybrids as a single drug therapy for CF caused by the ΔF508 mutation.
A uniquely efficacious type of CFTR corrector with complementary mode of action

Valentina Marchesin,Lucile Monnier,Peter Blattmann,Florent Chevillard,Christine Kuntz,Camille Forny,Judith Kamper,Rolf Studer,Alexandre Bossu,Eric A Ertel,Oliver Nayler,Christine Brotschi,Jodi T Williams,John Gatfield,Eric A. Ertel,Jodi T. Williams

DOI: https://doi.org/10.1126/sciadv.adk1814

IF: 13.6

2024-03-02

Science Advances

Abstract:Three distinct pharmacological corrector types (I, II, III) with different binding sites and additive behavior only partially rescue the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding and trafficking defect observed in cystic fibrosis. We describe uniquely effective, macrocyclic CFTR correctors that were additive to the known corrector types, exerting a complementary "type IV" corrector mechanism. Macrocycles achieved wild-type–like folding efficiency of F508del-CFTR at the endoplasmic reticulum and normalized CFTR currents in reconstituted patient-derived bronchial epithelium. Using photo-activatable macrocycles, docking studies and site-directed mutagenesis a highly probable binding site and pose for type IV correctors was identified in a cavity between lasso helix-1 (Lh1) and transmembrane helix-1 of membrane spanning domain (MSD)-1, distinct from the known corrector binding sites. Since only F508del-CFTR fragments spanning from Lh1 until MSD2 responded to type IV correctors, these likely promote cotranslational assembly of Lh1, MSD1, and MSD2. Previously corrector-resistant CFTR folding mutants were also robustly rescued, suggesting substantial therapeutic potential for type IV correctors.

multidisciplinary sciences
Structure-based discovery of CFTR potentiators and inhibitors

Fangyu Liu,Anat Levit Kaplan,Jesper Levring,Jürgen Einsiedel,Stephanie Tiedt,Katharina Distler,Natalie S. Omattage,Ivan S. Kondratov,Yurii S. Moroz,Harlan L. Pietz,John J. Irwin,Peter Gmeiner,Brian K. Shoichet,Jue Chen

DOI: https://doi.org/10.1101/2023.09.09.557002

2024-03-11

Abstract:The cystic fibrosis transmembrane conductance regulator (CFTR) is a crucial ion channel whose loss of function leads to cystic fibrosis, while its hyperactivation leads to secretory diarrhea. Small molecules that improve CFTR folding (correctors) or function (potentiators) are clinically available. However, the only potentiator, ivacaftor, has suboptimal pharmacokinetics and inhibitors have yet to be clinically developed. Here we combine molecular docking, electrophysiology, cryo-EM, and medicinal chemistry to identify novel CFTR modulators. We docked ∼155 million molecules into the potentiator site on CFTR, synthesized 53 test ligands, and used structure-based optimization to identify candidate modulators. This approach uncovered novel mid-nanomolar potentiators as well as inhibitors that bind to the same allosteric site. These molecules represent potential leads for the development of more effective drugs for cystic fibrosis and secretory diarrhea, demonstrating the feasibility of large-scale docking for ion channel drug discovery.

Biophysics
Isoxazolopyrimidines As Novel ΔF508-CFTR Correctors.

Gui Jun Yu,Baoxue Yang,A. S. Verkman,Mark J. Kurth

DOI: https://doi.org/10.1055/s-0029-1219781

2010-01-01

Synlett

Abstract:Using a cell-based high-throughput screen, we identified isoxazolo[5,4-d]pyrimidines as novel small-molecule correctors of the cystic fibrosis mutant protein ΔF508-CFTR. 22 Isoxazolo[5,4-d]pyrimidine analogues were synthesized and tested. Synthesis of the key intermediate, 5-amino-3-arylisoxazole-4-carboxamide, was accomplished by nitrile oxide cycloaddition to (2-amino-1-cyano-2-oxoethyl)sodium. Formation of 3-arylisoxazolo-[5,4-d]pyrimidin-4(5H)-one and chlorination gave 4-chloro-3-arylisoxazolo[5,4-d]pyrimidine. Finally, functionalization at C-4 of the pyrimidine ring by nucleophilic substitution gave the targeted isoxazolo[5,4-d]pyrimidines. Six of the reported analogues had low micromolar potency for increasing halide transport in ΔF508-CFTR cells.
Searching for Combinations of Small-Molecule Correctors to Restore F508del–Cystic Fibrosis Transmembrane Conductance Regulator Function and Processing

Clément Boinot,Mathilde Jollivet Souchet,Romain Ferru-Clément,Frédéric Becq

DOI: https://doi.org/10.1124/jpet.114.214890

2014-06-26

Journal of Pharmacology and Experimental Therapeutics

Abstract:The mutated protein F508del-cystic fibrosis transmembrane conductance regulator (CFTR) failed to traffic properly as a result of its retention in the endoplasmic reticulum and functions as a chloride (Cl(-)) channel with abnormal gating and endocytosis. Small chemicals (called correctors) individually restore F508del-CFTR trafficking and Cl(-) transport function, but recent findings indicate that synergistic pharmacology should be considered to address CFTR defects more clearly. We studied the function and maturation of F508del-CFTR expressed in HeLa cells using a combination of five correctors [miglustat, IsoLAB (1,4-dideoxy-2-hydroxymethyl-1,4-imino-l-threitol), Corr4a (N-[2-(5-chloro-2-methoxy-phenylamino)-4'-methyl-[4,5']bithiazolyl-2'-yl]-benzamide), VX-809 [3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid], and suberoylamilide hydroxamic acid (SAHA)]. Using the whole-cell patch-clamp technique, the current density recorded in response to CFTR activators (forskolin + genistein) was significantly increased in the presence of the following combinations: VX-809 + IsoLAB; VX-809 + miglustat + SAHA; VX-809 + miglustat + IsoLAB; VX-809 + IsoLAB + SAHA; VX-809 + miglustat + IsoLAB + SAHA. These combinations restored the activity of F508del-CFTR but with a differential effect on the appearance of mature c-band of F508del-CFTR proteins. Focusing on the VX-809 + IsoLAB cocktail, we recorded a level of correction higher at 37°C versus room temperature, but without amelioration of the thermal instability of CFTR. The level of functional rescue with VX-809 + IsoLAB after 4 hours of incubation was maximal and similar to that obtained in optimal conditions of use for each compound (i.e., 24 hours for VX-809 + 4 hours for IsoLAB). Finally, we compared the stimulation of F508del-CFTR by forskolin or forskolin + VX-770 [N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide] with cells corrected by VX-809 + IsoLAB. Our results open new perspectives for the development of a synergistic polypharmacology to rescue F508del-CFTR and show the importance of temperature on the effect of correctors and on the level of correction, suggesting that optimized combination of correctors could lead to a better rescue of F508del-CFTR function.

pharmacology & pharmacy
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling

Elvira Sondo,Valeria Tomati,Emanuela Caci,Alessia Isabella Esposito,Ulrich Pfeffer,Nicoletta Pedemonte,Luis J V Galietta

DOI: https://doi.org/10.1152/ajpcell.00507.2010

Abstract:The F508del mutation, the most frequent in cystic fibrosis (CF), impairs the maturation of the CFTR chloride channel. The F508del defect can be partially overcome at low temperature (27°C) or with pharmacological correctors. However, the efficacy of correctors on the mutant protein appears to be dependent on the cell expression system. We have used a bronchial epithelial cell line, CFBE41o-, to determine the efficacy of various known treatments and to discover new correctors. Compared with other cell types, CFBE41o- shows the largest response to low temperature and the lowest one to correctors such as corr-4a and VRT-325. A screening of a small-molecule library identified 9-aminoacridine and ciclopirox, which were significantly more effective than corr-4a and VRT-325. Analysis with microarrays revealed that 9-aminoacridine, ciclopirox, and low temperature, in contrast to corr-4a, cause a profound change in cell transcriptome. These data suggest that 9-aminoacridine and ciclopirox act on F508del-CFTR maturation as proteostasis regulators, a mechanism already proposed for the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). However, we found that 9-aminoacridine, ciclopirox, and SAHA, in contrast to corr-4a, VRT-325, and low temperature, do not increase chloride secretion in primary bronchial epithelial cells from CF patients. These conflicting data appeared to be correlated with different gene expression signatures generated by these treatments in the cell line and in primary bronchial epithelial cells. Our results suggest that F508del-CFTR correctors acting by altering the cell transcriptome may be particularly active in heterologous expression systems but markedly less effective in native epithelial cells.
[Behavior of 2 different neighboring tumors induced by methylcholanthrene in mice].

Z. Albert,H. Starzyk

1967-04-01

Abstract:
Quantifying exposure to vero-cytotoxigenic Escherichia coli O157 in milk sold as pasteurized: a model-based approach.

H. Clough,D. Clancy,N. French

DOI: https://doi.org/10.1016/j.ijfoodmicro.2008.12.036

2009-05-31

Abstract:
Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations

Venkateshwar Mutyam,Jyoti Sharma,Yao Li,Ning Peng,Jianguo Chen,Li Ping Tang,Emily Falk Libby,Ashvani K Singh,Katja Conrath,Steven M Rowe,Ashvani K. Singh,Steven M. Rowe

DOI: https://doi.org/10.1165/rcmb.2019-0291oc

IF: 7.748

2021-05-01

American Journal of Respiratory Cell and Molecular Biology

Abstract:Premature-termination codons (PTCs) in CFTR (cystic fibrosis [CF] transmembrane conductance regulator) result in nonfunctional CFTR protein and are the proximate cause of ∼11% of CF-causing alleles, for which no treatments exist. The CFTR corrector lumacaftor and the potentiator ivacaftor improve CFTR function with terminal PTC mutations and enhance the effect of readthrough agents. Novel correctors GLPG2222 (corrector 1 [C1]), GLPG3221 (corrector 2 [C2]), and potentiator GLPG1837 compare favorably with lumacaftor and ivacaftor in vitro. Here, we evaluated the effect of correctors C1a and C2a (derivatives of C1 and C2) and GLPG1837 alone or in combination with the readthrough compound G418 on CFTR function using heterologous Fischer rat thyroid (FRT) cells, the genetically engineered human bronchial epithelial (HBE) 16HBE14o- cell lines, and primary human cells with PTC mutations. In FRT lines pretreated with G418, GLPG1837 elicited dose-dependent increases in CFTR activity that exceeded those from ivacaftor in FRT-W1282X and FRT-R1162X cells. A three-mechanism strategy consisting of G418, GLPG1837, and two correctors (C1a + C2a) yielded the greatest functional improvements in FRT and 16HBE14o- PTC variants, noting that correction and potentiation without readthrough was sufficient to stimulate CFTR activity for W1282X cells. GLPG1837 + C1a + C2a restored substantial function in G542X/F508del HBE cells and restored even more function for W1282X/F508del cells, largely because of the corrector/potentiator effect, with no additional benefit from G418. In G542X/R553X or R1162X/R1162X organoids, enhanced forskolin-induced swelling was observed with G418 + GLPG1837 + C1a + C2a, although GLPG1837 + C1a + C2a alone was sufficient to improve forskolin-induced swelling in W1282X/W1282X organoids. Combination of CFTR correctors, potentiators, and readthrough compounds augments the functional repair of CFTR nonsense mutations, indicating the potential for novel correctors and potentiators to restore function to truncated W1282X CFTR.

biochemistry & molecular biology,cell biology,respiratory system
4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing

Choong Leol Yoo,Gui Jun Yu,Baoxue Yang,Lori I. Robins,A.S. Verkman,Mark J. Kurth

DOI: https://doi.org/10.1016/j.bmcl.2008.03.037

IF: 2.94

2008-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:The synthesis and ΔF508-CFTR corrector activity of a 148-member methylbithiazole-based library are reported. Synthetic routes were devised and optimized to generate methylbithiazole analogs in four steps. Corrector potency and efficacy were assayed using epithelial cells expressing human ΔF508-CFTR. These structure–activity data establish that the bithiazole substructure plays a critical function; eight novel methylbithiazole correctors were identified with low micromolar potencies.
Stabilizing Rescued Delf508 CFTR at the Plasma Membrane by Potentiation of Its Interaction with Na+/H+ Exchanger Regulatory Factor 1

K. Arora,C. C. Moon,W. Zhang,H. Penmatsa,A. Ren,S. Yarlagadda,C. Sinha,A. Naren

DOI: https://doi.org/10.1096/fasebj.27.1_supplement.553.4

2013-01-01

Abstract:Cystic fibrosis (CF) is a lethal genetic disease and warrants effective therapeutic interventions. Preclinical studies screened CF‐correctors based on their ability to partially correct the processing defects of ΔF508 mutation of cystic fibrosis transmembrane conductance regulator (CFTR), the most common CF causing mutation. The CF‐corrector VX‐809 underwent Phase II trials in combination with VX‐770 or Ivacaftor and was shown to significantly improve lung function in CF patients. In this study, we demonstrate the significance of protein‐protein interaction in enhancing the stability of mutant channel protein at the plasma membrane. We show that VX‐809 partially stabilizes ΔF508‐CFTR interaction with scaffolding protein Na+/H+ exchanger regulatory factor 1 (NHERF1) at the plasma membrane. We demonstrate in cystic fibrosis bronchial epithelial cells that VX‐809 increases half‐life of ΔF508 CFTR at the plasma membrane by potentiating its otherwise weak interaction with NHERF1. Single particle tracking analysis further strengthens our observation as VX‐809 restricts the mobility of ΔF508‐CFTR at the plasma membrane while the effect is mitigated in ΔF508 CFTR His10 (lacks the PDZ motif and hence the ability to interact with NHERF1). Therefore, our studies demonstrate the importance of macromolecular complex in rescuing mutant CFTR to the plasma membrane and will further help device newer generation of more effective CF‐correctors.

Behavioral, Clinical, and Pathological Characterization of Acid Metalliferous Water Toxicity in Mallards

Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

[Mucoadhesive oral tablets--a modern dosage form with controlled drug release].

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors

Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

Perceptual Comparisons with Pictures and Environmental Sounds

Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.

When lightning strikes.

Design and synthesis of a hybrid potentiator–corrector agonist of the cystic fibrosis mutant protein ΔF508-CFTR

A uniquely efficacious type of CFTR corrector with complementary mode of action

Structure-based discovery of CFTR potentiators and inhibitors

Isoxazolopyrimidines As Novel ΔF508-CFTR Correctors.

Searching for Combinations of Small-Molecule Correctors to Restore F508del–Cystic Fibrosis Transmembrane Conductance Regulator Function and Processing

Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling

[Behavior of 2 different neighboring tumors induced by methylcholanthrene in mice].

Quantifying exposure to vero-cytotoxigenic Escherichia coli O157 in milk sold as pasteurized: a model-based approach.

Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations

4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing

Stabilizing Rescued Delf508 CFTR at the Plasma Membrane by Potentiation of Its Interaction with Na+/H+ Exchanger Regulatory Factor 1